The company’s Grafix product for the ulcers was three times more effective than the control. A cross-over phase where those given the control were switched to Grafix showed similarly dramatic results.
Wounds that won’t heal are a huge health problem in medicine so Osiris’ impressive results have huge implications. I see this also more broadly as a giant step forward for the cellular medicine field. The stock (OSIR) more than doubled so far today in PPS.
Note: I changed the title & some content from the original version of the post focused on the “stem cell” field to the “cellular medicine” field out of an abundance of caution.
Disclosure: I do not own any stock in Osiris.